Navigation Links
Adeona Announces HartLab Expansion Into Microbiology Testing Services
Date:6/15/2010

>About Adeona Pharmaceuticals, Inc.

Adeona (AMEX: AEN) is a pharmaceutical company developing new medicines for serious central nervous systems diseases. Adeona's primary strategy is to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them to an inflection point in valuation resulting in a significant development and marketing collaboration. Trimesta (estriol) is an investigational oral drug for the treatment of relapsing remitting multiple sclerosis. A 150-patient, 16-center, randomized, double-blind, placebo-controlled clinical trial is currently underway. Effirma (flupirtine) is a centrally-acting investigational oral drug for the treatment of fibromyalgia syndrome. Adeona has entered into a potential $17.5 million corporate partnership with Meda AB. As part of the agreement, Meda will assume all future development costs while Adeona is entitled to receive milestone payments and royalties. Zinthionein ZC (zinc cysteine) is an oral, gastro-retentive, sustained-release medical food candidate being developed for the dietary management of Alzheimer's disease and mild cognitive impairment. A 60-patient randomized double-blind, placebo-controlled clinical study is currently underway. dnaJP1 (hsp peptide) is an investigational oral drug for the treatment of rheumatoid arthritis. It has completed a 160-patient, multi-center, randomized, double-blind, placebo-controlled clinical trial. ZincMonoCysteine (zinc-monocysteine) is an investigational oral drug for the treatment of dry age-related macular degeneration. It has completed an 80-patient, randomized, double-blind, placebo-controlled clinical trial. Further information on the company is available at

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
2. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
3. Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
5. Acuo Technologies Announces Implementation and Acceptance of Acuos DICOM Services Grid(TM) With Lancaster General Hospital
6. Perrigo Announces FDA Final Approval for Miconazole
7. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
8. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
9. GSK Announces Revised Product Labels for Serevent® and Advair®
10. US Oncology Announces iKnowMed(TM) Technology Platform
11. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... July 14, 2014  Mylan Inc. (NASDAQ: MYL ... agreement with Abbott (NYSE: ... non-U.S. developed markets specialty and branded generics business ("the ... will receive 105 million shares of the combined ... of $50.20 on Friday, July 11, 2014, representing an approximately ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... 11, 2010 Thoratec Corporation (Nasdaq: THOR ... therapies to save, support and restore failing hearts, said ... Tuesday, November 16 at the American Heart Association (AHA) ... and chief executive officer of Thoratec, will be discussing ...
... 2010 Ardea Biosciences, Inc. (Nasdaq: RDEA ... trials of BAY 86-9766 (formerly known as RDEA119) will ... and Treatment of Cancer (EORTC) – National Cancer Institute ... on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany. ...
Cached Medicine Technology:Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 3Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 4
(Date:7/14/2014)... 2014 Acute coronary syndrome (ACS) ... healthcare costs, frequent recurrences and hospitalizations, and high ... ACS incidence increases with age and will be ... population increases around the world. ACS is classified ... heart muscle damage inferred from a person’s symptoms, ...
(Date:7/14/2014)... 14, 2014 Georgia State University ... groups under the fifth round of its Second ... of research and academic performance. , The ... of top-notch faculty members to the university, with ... in areas of national significance. , “With the ...
(Date:7/14/2014)... through the bloodstream, homing in on a sheath ... and metastasize to other organs, scientists at The ... in Cancer Cell . , "This completely ... provides new potential avenues to predict and prevent ... M.D., professor of Gynecologic Oncology and Reproductive Medicine ...
(Date:7/14/2014)... look back on 40 years of the Glasgow Coma Scale ... and clinical practice, in a new Personal View published in ... Personal View is published on the 40th anniversary of the ... Since this seminal publication, the Glasgow Coma Scale has provided ... level, the clinical hallmark of acute brain injury. The scale ...
(Date:7/14/2014)... D.C., July 14, 2014 A recent study published ... of the American Academy of Child and Adolescent Psychiatry ... the age of onset criterion for diagnosis of attention-deficit/hyperactivity ... for ADHD, previously set at 7 in DSM-IV, has ... of onset is now set at 12, rather than ...
Breaking Medicine News(10 mins):Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 2Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 3Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 4Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 2Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 3Health News:MD Anderson researchers discover new route for ovarian cancer spread 2Health News:MD Anderson researchers discover new route for ovarian cancer spread 3
... a novel study on condom use with help from ,scientists, ... the significance of condom use in curtailing spread of AIDS. ... study on a request from Pope Benedict XVI. The cardinal ... abstinence from sex in the fight against AIDS. ...
... has been approved by the Food and Drug Administration ... cyanide poisoning//. The kit contains the drug hydroxocobalamin, intravenous ... enables emergency treatment for known or suspected cyanide poisoning. ... to emergencies including possible attacks by terrorists is enhanced. ...
... people seeking medical help because of illnesses related to alcohol ... few years//. ,Current official statistics show that ... treated for accidents and emergencies caused due to drunkenness ... for the same also have doubled, reported NHS since 1997, ...
... given rise not only to high expectations of treatment ... the German Research Foundation, Deutsche Forschungsgemeinschaft (DFG) issued its ... developed enormously. ,The second memorandum, which ... on Genetic Research, makes it clear that gene therapy ...
... research study finds that 95 percent of Americans have pre ... new as American men //and women as far back as ... disappointed that spending hundreds of millions of dollars advising young ... being wasted. One official disagreed and opined that even if ...
... ingredient of psychedelic mushrooms, also called magic mushrooms ... disorder (OCD), according to a study// by University ... substances like psilocybin, psilocin, or muscimol. ,The ... 1970, according to AP reports. ,The intent ...
Cached Medicine News:Health News:Gene Therapy for Hereditary Immunodeficiency Diseases 2